Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, October 25, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Compugen to Significantly Expand Immuno-Oncology Activities During 2014
Wednesday, January 08, 2014
R&D expenditures for 2014 anticipated to increase by more than 60%.

New Anti-GABAB1 Receptor Antibody from AbboMax
Thursday, December 19, 2013
Recent progress in neuroscience research from the Company.

TELOS MicroPlate™ from Kinesis – a versatile 96-well SPE format for small volume biological fluid samples
Monday, December 16, 2013
The TELOS MicroPlate™ is a versatile 96-well plate for the extraction of drug molecules from small volume biological fluid samples.

Tecan’s Cavro® Air Displacement Pipettor
Wednesday, December 11, 2013
Proves ideal for new microbiology application.

York's Biology Department Buys their EM Supplies from Agar
Wednesday, December 11, 2013
Company provides microscopy services to researchers of all levels of expertise.

Cell Therapy Company Uses TAP’s Fill-It Automated Cryovial Processing System
Thursday, December 05, 2013
To rapidly produce consistent cancer immunotherapy batches and cell banks.

GE Healthcare Launches ÄKTA start
Tuesday, November 26, 2013
Easy-to-use preparative system for laboratory-scale protein purification.

Phosphorylation: One of the Hottest Topics in Cell Biology Research
Tuesday, November 26, 2013
Over 140 phosphospecific antibodies are developed in AbboMax, Inc.

Custom Phospho-Specific Antibody Production Service
Tuesday, November 26, 2013
Both reliable and produces highly specific quality antisera.

<< 3 4 5 6 7 8 9 >>
Showing Results 51 - 60 of 358
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv